Cognitive deficits and structural brain changes co-occur in patients with schizophrenia. Improving our understanding of the relationship between these is important to develop improved therapeutic strategies. Back-translation of these findings into rodent models for schizophrenia offers a potential means to achieve this goal.
Aims:
The purpose of this study was to determine the extent of structural brain changes and how these relate to cognitive behaviour in a sub-chronic phencyclidine rat model.
Methods:
Performance in the novel object recognition task was examined in female Lister Hooded rats at one and six weeks after sub-chronic phencyclidine (2 mg/kg intra-peritoneal, n=15) and saline controls (1 ml/kg intra-peritoneal, n=15). Locomotor activity following acute phencyclidine challenge was also measured. Brain volume changes were assessed in the same animals using ex vivo structural magnetic resonance imaging and computational neuroanatomical analysis at six weeks.
Results:
Female sub-chronic phencyclidine-treated Lister Hooded rats spent significantly less time exploring novel objects (p<0.05) at both time-points and had significantly greater locomotor activity response to an acute phencyclidine challenge (p<0.01) at 3–4 weeks of washout. At six weeks, sub-chronic phencyclidine-treated Lister Hooded rats displayed significant global brain volume reductions (p<0.05; q<0.05), without apparent regional specificity. Relative volumes of the perirhinal cortex however were positively correlated with novel object exploration time only in sub-chronic phencyclidine rats at this time-point.
Conclusion:
A sustained sub-chronic phencyclidine-induced cognitive deficit in novel object recognition is accompanied by global brain volume reductions in female Lister Hooded rats. The relative volumes of the perirhinal cortex however are positively correlated with novel object exploration, indicating some functional relevance.
Abdul-MonimZNeillJCReynoldsGP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol21: 198–205.
2.
BarnesSASawiakSJCaprioliD, et al. (2014) Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int J Neuropsychopharmacol18: pii: pyu010. doi: 10.1093/ijnp/pyu010.
3.
BoraEPantelisC (2015) Meta-analysis of cognitive impairment in first-episode bipolar disorder: Comparison with first-episode schizophrenia and healthy controls. Schizophr Bull41: 1095–1104.
4.
BortolatoBMiskowiakKWKohlerCA, et al. (2015) Cognitive dysfunction in bipolar disorder and schizophrenia: A systematic review of meta-analyses. Neuropsychiatr Dis Treat11: 3111–3125.
5.
BrandtCLDoanNTTonnesenS, et al. (2015) Assessing brain structural associations with working-memory related brain patterns in schizophrenia and healthy controls using linked independent component analysis. Neuroimage Clin9: 253–263.
6.
BrownMWAggletonJP (2001) Recognition memory: What are the roles of the perirhinal cortex and hippocampus?Nat Rev Neurosci2: 51–61.
7.
BruggerSPHowesOD (2017) Heterogeneity and homogeneity of regional brain structure in schizophrenia a meta-analysis. JAMA Psychiatry74: 1104–1111.
8.
CadinuDGraysonBPoddaG, et al. (2018) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology142: 41–62.
9.
ChangEHHuertaPT (2012) Neurophysiological correlates of object recognition in the dorsal subiculum. Front Behav Neurosci6: 46.
10.
ChestersRStoneJMWoodTC, et al. (2017) Neuroadaptations to chronic ketamine exposure: A parallel human and mouse MRI imaging study. Biol Psychiatry81: S118.
11.
CrumWRSawiakSJChegeW, et al. (2017) Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study. Brain Behav Immun63: 50–59.
12.
DawsonNHighamDJMorrisBJ, et al. (2010) Alterations in functional brain network structure induced by subchronic phencyclidine (PCP) treatment parallel those seen in schizophrenia. J Psychopharmacol24: a18.
13.
DawsonNMorrisBJPrattJA (2015) Functional brain connectivity phenotypes for schizophrenia drug discovery. J Psychopharmacol29: 169–177.
14.
DawsonNXiaoXLMcdonaldM, et al. (2014) Sustained NMDA receptor hypofunction induces compromised neural systems integration and schizophrenia-like alterations in functional brain networks. Cereb Cortex24: 452–464.
15.
DempsterKNormanRThebergeJ, et al. (2017) Cognitive performance is associated with gray matter decline in first-episode psychosis. Psychiatry Res Neuroimaging264: 46–51.
16.
DumitriuDHaoJHaraY, et al. (2010) Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment. J Neurosci30: 7507–7515.
17.
Edward RobertsRCurranHVFristonKJ, et al. (2014) Abnormalities in white matter microstructure associated with chronic ketamine use. Neuropsychopharmacology39: 329–38.
18.
ElsworthJDMorrowBAHajszanT, et al. (2011) Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine. Neuropsychopharmacology36: 2054–2061.
19.
FixASWozniakDFTruexLL, et al. (1995) Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res696: 194–204.
20.
GenoveseCRLazarNANicholsT (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage15: 870–878.
21.
GilbertPEKesnerRP (2003) Recognition memory for complex visual discriminations is influenced by stimulus interference in rodents with perirhinal cortex damage. Learn Mem10: 525–530.
22.
GlantzLALewisDA (2001) Dendritic spine density in schizophrenia and depression. Arch Gen Psychiatry58: 203–203.
23.
GozziALargeCHSchwarzA, et al. (2008) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology33: 1690–1703.
24.
GraysonBIdrisNFNeillJC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res184: 31–38.
25.
GraysonBLegerMPiercyC, et al. (2015) Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav Brain Res285: 176–193.
26.
GreenMF (2006) Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry67(Suppl 9): 3–8; discussion 36–42.
27.
HaijmaSVVan HarenNCahnW, et al. (2013) Brain volumes in schizophrenia: A meta-analysis in over 18 000 subjects. Schizophr Bull39: 1129–1138.
28.
HajszanTLeranthCRothRH (2006) Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry60: 639–644.
29.
HamburgHTrossbachSVBaderV, et al. (2016) Simultaneous effects on parvalbumin-positive interneuron and dopaminergic system development in a transgenic rat model for sporadic schizophrenia. Sci Rep6: 34946.
30.
HeinrichsRWPinnockFParlarM, et al. (2017) Cortical thinning in network-associated regions in cognitively normal and below-normal range schizophrenia. Schizophr Res Treatment2017: 1–7.
31.
JanhunenSKSvärdHTalposJ, et al. (2015) The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacology (Berl)232: 4059–4083.
32.
JirsaraieRJSheffieldJMBarchDM (2018) Neural correlates of global and specific cognitive deficits in schizophrenia. Schizophr Res201: 237–242.
33.
Karnik-HenryMSWangLBarchDM, et al. (2012) Medial temporal lobe structure and cognition in individuals with schizophrenia and in their non-psychotic siblings. Schizophr Res138: 128–135.
34.
KasaiHFukudaMWatanabeS, et al. (2010) Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci33: 121–129.
35.
KeiferOPHurtRCGutmanDA, et al. (2015) Voxel-based morphometry predicts shifts in dendritic spine density and morphology with auditory fear conditioning. Nat Commun6: 7582.
36.
KimJSKornhuberHHSchmid-BurgkW, et al. (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett20: 379–382.
37.
KinnavaneLAminEOlarte-SanchezCM, et al. (2016) Detecting and discriminating novel objects: The impact of perirhinal cortex disconnection on hippocampal activity patterns. Hippocampus26: 1393–1413.
38.
KrystalJHKarperLPSeibylJP, et al. (1994) Subanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry51: 199–214.
39.
LahtiACHolcombHHMedoffDR, et al. (1995a) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport6: 869–872.
40.
LahtiACKoffelBLaporteD, et al. (1995b) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology13: 9–19.
41.
LauJCLerchJPSledJG, et al. (2008) Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer’s disease. Neuroimage42: 19–27.
42.
LegerMAlvaroGLargeC, et al. (2015) AUT6, a novel Kv3 channel modulator, reverses cognitive and neurobiological dysfunction in a rat model of relevance to schizophrenia symptomatology. Eur Neuropsychopharmacol25: S480.
43.
LerchJPCarrollJBDorrA, et al. (2008a) Cortical thickness measured from MRI in the YAC128 mouse model of Huntington’s disease. Neuroimage41: 243–251.
44.
LerchJPCarrollJBSpringS, et al. (2008b) Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage39: 32–39.
45.
LerchJPGazdzinskiLGermannJ, et al. (2012) Wanted dead or alive? The tradeoff between in-vivo versus ex-vivo MR brain imaging in the mouse. Front Neuroinform6: 6.
46.
LiaoYTangJCorlettPR, et al. (2011) Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry69: 42–48.
47.
LiaoYTangJMaM, et al. (2010) Frontal white matter abnormalities following chronic ketamine use: A diffusion tensor imaging study. Brain133: 2115–2122.
48.
MasseySHSternDAldenEC, et al. (2017) Cortical thickness of neural substrates supporting cognitive empathy in individuals with schizophrenia. Schizophr Res179: 119–124.
49.
McLeanSLGraysonBIdrisNF, et al. (2011) Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol21: 333–343.
50.
McLeanSLHarteMKNeillJC, et al. (2017) Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation. J Psychopharmacol31: 660–666.
51.
MoghaddamBJavittD (2012) From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology37: 4–15.
52.
MorillasEGomez-ChaconBGalloM (2017) Flavor and object recognition memory impairment induced by excitotoxic lesions of the perirhinal cortex. Neurobiol Learn Mem144: 230–234.
53.
NeillJCBarnesSCookS, et al. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on nmda receptor antagonism. Pharmacol Ther128: 419–432.
54.
NeillJCHarteMKHaddadPM, et al. (2014) Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans. Eur Neuropsychopharmacol24: 822–835.
55.
PappEALeergaardTBCalabreseE, et al. (2014) Waxholm Space atlas of the Sprague Dawley rat brain. Neuroimage97: 374–386.
56.
PetersASetharesCLuebkeJI (2008) Synapses are lost during aging in the primate prefrontal cortex. Neuroscience152: 970–981.
57.
PetersJScofieldMDReichelCM (2018) Chemogenetic activation of the perirhinal cortex reverses methamphetamine-induced memory deficits and reduces relapse. Learn Mem25: 410–415.
58.
PrattJWinchesterCDawsonN, et al. (2012) Advancing schizophrenia drug discovery: Optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov11: 560–579.
59.
ReynoldsGPNeillJC (2016) Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. J Psychopharmacol30: 1141–1144.
60.
RichettoJChestersRCattaneoA, et al. (2017) Genome-wide transcriptional profiling and structural magnetic resonance imaging in the maternal immune activation model of neurodevelopmental disorders. Cereb Cortex27: 3397–3413.
61.
SawiakSJWoodNIWilliamsGB, et al. (2009a) Deformation-based morphometry in the R6/2 Huntington’s disease mouse brain. Proc Int Soc Magn Reson Imaging17: 545.
62.
SawiakSJWoodNIWilliamsGB, et al. (2009b) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis33: 20–27.
63.
SchwarzEDoanNTPergolaG, et al. (2019) Reproducible grey matter patterns index a multivariate, global alteration of brain structure in schizophrenia and bipolar disorder. Transl Psychiatry9: 12.
64.
ShelnuttSRGunnellMOwensSM (1999) Sexual dimorphism in phencyclidine in vitro metabolism and pharmacokinetics in rats. J Pharmacol Exp Ther290: 1292–1298.
65.
SnigdhaSNeillJCMcLeanSL, et al. (2011) Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J Mol Neurosci43: 337–345.
66.
StolpHBBallGSoPW, et al. (2018) Voxel-wise comparisons of cellular microstructure and diffusion-MRI in mouse hippocampus using 3D bridging of optically-clear histology with neuroimaging data (3D-BOND). Sci Rep8: 4011.
67.
TanimizuTKonoKKidaS (2018) Brain networks activated to form object recognition memory. Brain Res Bull141: 27–34.
68.
Valdes-HernandezPASumiyoshiANonakaH, et al. (2011) An in vivo MRI template set for morphometry, tissue segmentation, and fMRI localization in rats. Front Neuroinform5: 26.
69.
van EedeMCScholzJChakravartyMM, et al. (2013) Mapping registration sensitivity in MR mouse brain images. Neuroimage82: 226–236.
70.
van ErpTGHibarDPRasmussenJM, et al. (2016) Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the enigma consortium. Mol Psychiatry21: 547–553.
71.
van ErpTGMWaltonEHibarDP, et al. (2018) Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. Biol Psychiatry84: 644–654.
72.
VernonACCrumWRLerchJP, et al. (2014) Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol Psychiatry75: 982–990.
73.
VernonACNatesanSModoM, et al. (2011) Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry69: 936–944.
74.
WaltonEHibarDPVan ErpTGM, et al. (2018) Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. Psychol Med48: 82–94.
75.
WaltonEHibarDPVan ErpTGM, et al. (2017) Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA schizophrenia consortium. Acta Psychiatrica Scandinavica135: 439–447.
76.
WeibleAPRowlandDCPangR, et al. (2009) Neural correlates of novel object and novel location recognition behavior in the mouse anterior cingulate cortex. J Neurophysiol102: 2055–2068.
77.
WintersBDSaksidaLMBusseyTJ (2008) Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev32: 1055–1070.
78.
WoodTCSimmonsCHurleySA, et al. (2016) Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model. PeerJ4: e2632.
79.
WuHWangXGaoY, et al. (2016) NMDA receptor antagonism by repetitive MK801 administration induces schizophrenia-like structural changes in the rat brain as revealed by voxel-based morphometry and diffusion tensor imaging. Neuroscience322: 221–233.
80.
XiuYKongXRZhangL, et al. (2014) White matter injuries induced by MK-801 in a mouse model of schizophrenia based on NMDA antagonism. Anat Rec (Hoboken)297: 1498–1507.
81.
XiuYKongXRZhangL, et al. (2015) The myelinated fiber loss in the corpus callosum of mouse model of schizophrenia induced by MK-801. J Psychiatr Res63: 132–140.
82.
ZatorreRJFieldsRDJohansen-BergH (2012) Plasticity in gray and white: Neuroimaging changes in brain structure during learning. Nat Neurosci15: 528–536.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
